Premium
Effects of Recombinant Cholera Toxin B Subunit (rCTB) on Cellular Immune Responses: Enhancement of Delayed‐Type Hypersensitivity Following Intranasal Co‐Administration of Mycobacterium bovis ‐BCG with rCTB
Author(s) -
Maeyama Junichi,
Isaka Masanori,
Yasuda Yoko,
Matano Keiko,
Morokuma Kazunori,
Ohkuma Kunio,
Tochikubo Kunio,
Yamamoto Saburo,
Goto Norihisa
Publication year - 2004
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.2004.tb03536.x
Subject(s) - microbiology and biotechnology , cholera toxin , immune system , biology , adjuvant , nasal administration , spleen , antigen , cellular immunity , immunology
Recombinant cholera toxin B subunit (rCTB) is a safe and potent mucosal adjuvant. To gain insight into the mechanism underlying the adjuvant effect of rCTB, the effects of rCTB on cell‐mediated immune responses of mice and guinea pigs were examined after intranasal administration of Mycobacterium bovis ‐bacillus Calmette‐Guérin (BCG) with and without rCTB. Delayed‐type hypersensitivity, for skin reactions in guinea pigs and for footpad swelling reactions in mice, to purified protein derivative (PPD) were enhanced by intranasal co‐administration of BCG and rCTB, as compared to giving BCG alone to these animals. Moreover, tumor necrosis factor (TNF)‐α and interferon (IFN)‐γ production of spleen cells and antigen specific spleen cell proliferation, stimulated with PPD, were enhanced in the presence of rCTB. These results strongly suggest that rCTB enhances cellular as well as humoral immune responses.